Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

e neutropenia (20%), and cardiac failure (3%).

"Although there are a number of treatment regimens that have been studied as salvage therapies in patients with relapsed aggressive NHL, few have demonstrated a high proportion of complete responses and many of the remissions achieved are of relatively short duration," said Jack W. Singer, M.D. Chief Medical Officer at CTI. "Patients who have completed a course of CHOP therapy are unable to be retreated with the same regimen due to the potential for severe heart toxicity when the lifetime limit of doxorubicin is exceeded.  Pixantrone has substantially less cardiotoxicity than doxorubicin in animal models and was found to be adequately tolerated in patients treated with prior doxorubicin in phase I trials.  The present study suggests that use of pixantrone with CPOP not only offers a high response rate, but in some patients these responses had impressive durability.  Four patients in the study had unmaintained remissions of between 4+ and 6+ years duration following CPOP, which is highly unusual in the setting of treating relapsed disease. The opportunity to re-challenge patients with a CHOP-like regimen, using pixantrone instead of doxorubicin after relapse from initial therapy with CHOP indicates that pixantrone-based regimens may represent a new approach to managing relapsed aggressive NHL. A Phase III clinical trial with pixantrone in this setting has recently been initiated, the PIX-R TRIAL™."

About Pixantrone and the CPOP Regimen

This trial examines the safety and potential efficacy of pixantrone (CPOP) when it is used in place of doxorubicin in the CHOP regimen for patients with relapsed aggressive NHL who had failed at least one prior treatment.  

Patients received up to six cycles of CPOP therapy. Cycles were every 21 days.  The phase I dose level was 80-180 mg/m for phase I, and the phase II recommended dose was 150 mg/m2. For both phases, dosing
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... May 29, 2015 Research and Markets ... the "Global A Dialyzer Reprocessing Machine (A ... to their offering. The Global A ... Report 2014 is a professional and in-depth study ... reprocessing machine industry. The report provides a ...
(Date:6/1/2015)...  Boston Biomedical, an industry leader in the development ... (CSC) pathways, will present clinical data today on the ... at the 2015 American Society of Clinical Oncology (ASCO) ... Data presented at ASCO highlight the potential of ... leading to inhibition of the critical genes for maintaining ...
(Date:6/1/2015)... , June 1, 2015   OTC ... Open, Transparent and Connected financial marketplaces for 10,000 ... a San Diego -based biopharmaceutical ... on OTCQB®, America,s only public venture market for ... - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO "We,re ...
Breaking Medicine Technology:Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... DIEGO, Dec. 20, 2010 Optimer Pharmaceuticals, Inc. ... Gregory Papaz has joined Optimer as Senior Vice ... the preparations for the planned commercialization of fidaxomicin. ... of experience in the healthcare and pharmaceutical industry ...
... XI,AN, China, Dec. 20, 2010 /PRNewswire-Asia-FirstCall/ -- DK Sinopharma, Inc. (OTC ... was honored at a grand awards ceremony on December 8, 2010 ... Paying Credit Rating on September 30, 2010. "We ... third time in a row that the Company has been rated ...
Cached Medicine Technology:Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations 2Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations 3DK Sinopharma, Inc. is Honored as 'A-class Taxpayer' for the Third Time 2DK Sinopharma, Inc. is Honored as 'A-class Taxpayer' for the Third Time 3
(Date:6/1/2015)... Sharenote, a leading web-base electronic healthcare software (EHR) is ... in Louisiana. The entrepreneurial trio behind Sharenote, will travel ... providers with the tools and resources to monitor key ... network. , Find out why Sharenote is the ... than 250 practices. , Four Day Schedule ...
(Date:6/1/2015)... There’s never a good time to be sick and need ... , As of June 1, OSF HealthCare is offering ... the Internet. Patients throughout Illinois can access care whenever they ... busy. We know that getting in to see a provider ... it easier,” said Jeffry Tillery, MD, Chief Transformation Officer for ...
(Date:6/1/2015)... Hexagon Geospatial is pleased to announce the launch ... service that provides on-demand access to the company’s world-class ... IMAGINE and GeoMedia are now available ... subscription model for delivering software products as an online ... quickly and easily access the right tools that help ...
(Date:6/1/2015)... June 01, 2015 Good360 announced ... the Irene W. and C.B. Pennington Foundation, Louisiana’s ... board of directors. Bertman joins Good360 just before ... this summer. , "Bringing with her many years ... am thrilled that Lori is joining the Good360 ...
(Date:6/1/2015)... Triple C announced today that they will be ... this year on RFD-TV. , From the humble, farm shop ... the today’s full line of rugged products, Triple C, Inc. ... , In this segment, American Farmer will explore how ... thrive in the tough conditions on North American ranches. Viewers ...
Breaking Medicine News(10 mins):Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 3Health News:Lori Bertman Joins Good360 Board of Directors 2Health News:Triple C to Be Featured in Upcoming Episode of American Farmer 2
... non-serious side effects , , FRIDAY June 27 (HealthDay News) ... marijuana plant don,t increase the risk of serious side ... non-serious side effects, Canadian scientists report. , The researchers ... British Columbia (UBC) examined adverse events reported in 31 ...
... (PTCB), the leading national program that has ... and congratulates the Florida House of Representatives ... requiring new standards for pharmacy technicians. The ... toward increasing patient safety for consumers. The ...
... /PRNewswire-FirstCall/,-- Schering-Plough Corp. (NYSE: SGP ) and ... the withdrawal of the New Drug Application (NDA) ... terminated the Schering-Plough/Merck Pharmaceuticals,respiratory joint venture, which was ... fixed-combination product that would combine loratadine and,montelukast. This ...
... 27 Health care facilities,in the U.S. are ... infections (HAI). Could there be hidden areas of,infection ... education program,from the production company Mission Critical attempts ... Areas of Infection,",( http://www.missioncriticaltv.com/index-8-1.html ) documents how an ...
... to the latest,report by the American Lung Association, Lung ... increasing while death rates due to other,leading causes of ... Chronic obstructive pulmonary disease (COPD) is expected to,become the ... American Lung Association publishes Lung Disease Data to serve ...
... a World Health Organization expert on E. coli ... Bioniche Life Sciences,Inc. (TSX: BNC), a research-based, technology-driven ... this week,entitled, "E. coli O157 Vaccine: Added Value ... from the food industry: Beef,dairy, and other agricultural ...
Cached Medicine News:Health News:Drugs With Marijuana Compounds Don't Boost Adverse Events 2Health News:Pharmacy Technician Certification Board (PTCB) Supports Florida's New Patient Safety Solution 2Health News:Pharmacy Technician Certification Board (PTCB) Supports Florida's New Patient Safety Solution 3Health News:Hidden Areas of Infection in U.S. Hospitals 2Health News:Hidden Areas of Infection in U.S. Hospitals 3Health News:American Lung Association Report Finds Lung Disease Death Rates Increasing While Cancer, Heart Disease and Stroke Death Rates Are Decreasing 2Health News:American Lung Association Report Finds Lung Disease Death Rates Increasing While Cancer, Heart Disease and Stroke Death Rates Are Decreasing 3Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 2Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 3Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 4Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 5
... Accurate Quantitation of DNA, RNA, Or Fluorescent ... and RNA is critical to life science research. ... way to measure quantities as small as 1ng/ml ... another set of excitation and emission filters, the ...
The Fluoroskan Ascent FL is equipped with both fluorometric and luminometric measurement technologies, providing a full coverage for fluorometric, glow and flash luminometric applications even in the...
... DyNA Quant™ 200 is a ... excitation and 460 nm emission. The ... the detection of double-stranded DNA using ... assay, which minimizes interference from the ...
... is a multifunctional single ... give you utmost flexibility ... and absorbance. Modulus operates ... dedicated luminometer, or a ...
Medicine Products: